177 related articles for article (PubMed ID: 37507044)
21. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.
Joshi S; Sharabi A
Pharmacol Ther; 2022 Jul; 235():108114. PubMed ID: 35122833
[TBL] [Abstract][Full Text] [Related]
22. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
23. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.
Hanoteau A; Newton JM; Krupar R; Huang C; Liu HC; Gaspero A; Gartrell RD; Saenger YM; Hart TD; Santegoets SJ; Laoui D; Spanos C; Parikh F; Jayaraman P; Zhang B; Van der Burg SH; Van Ginderachter JA; Melief CJM; Sikora AG
J Immunother Cancer; 2019 Jan; 7(1):10. PubMed ID: 30646957
[TBL] [Abstract][Full Text] [Related]
24. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
25. Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness.
Barnestein R; Galland L; Kalfeist L; Ghiringhelli F; Ladoire S; Limagne E
Oncoimmunology; 2022; 11(1):2120676. PubMed ID: 36117524
[TBL] [Abstract][Full Text] [Related]
26. Reactivation of Anticancer Immunity by Resetting Interorgan Crosstalk in Immune-Suppressive Cells with a Nanoparticulated Anti-Inflammatory Drug.
Doi M; Tanaka H; Ohoto T; Miura N; Sakurai Y; Hatakeyama H; Akita H
Small; 2023 Apr; 19(16):e2205131. PubMed ID: 36703512
[TBL] [Abstract][Full Text] [Related]
27. Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer.
Chen Y; Sun J; Luo Y; Liu J; Wang X; Feng R; Huang J; Du H; Li Q; Tan J; Ren G; Wang X; Li H
J Transl Med; 2022 Dec; 20(1):615. PubMed ID: 36564797
[TBL] [Abstract][Full Text] [Related]
28. Pancreatic Tumor Microenvironment.
Wang K; He H
Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
[TBL] [Abstract][Full Text] [Related]
29. Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy.
Peng P; Lou Y; Wang S; Wang J; Zhang Z; Du P; Zheng J; Liu P; Xu LX
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36521929
[TBL] [Abstract][Full Text] [Related]
30. Immune microenvironment of gliomas.
Gieryng A; Pszczolkowska D; Walentynowicz KA; Rajan WD; Kaminska B
Lab Invest; 2017 May; 97(5):498-518. PubMed ID: 28287634
[TBL] [Abstract][Full Text] [Related]
31. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
Yang M; Li J; Gu P; Fan X
Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
[TBL] [Abstract][Full Text] [Related]
32. Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function.
La Fleur L; Botling J; He F; Pelicano C; Zhou C; He C; Palano G; Mezheyeuski A; Micke P; Ravetch JV; Karlsson MCI; Sarhan D
Cancer Res; 2021 Feb; 81(4):956-967. PubMed ID: 33293426
[TBL] [Abstract][Full Text] [Related]
33. Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation.
Yang Y; Li C; Liu T; Dai X; Bazhin AV
Front Immunol; 2020; 11():1371. PubMed ID: 32793192
[TBL] [Abstract][Full Text] [Related]
34. NKG2D-Fc fusion protein promotes antitumor immunity through the depletion of immunosuppressive cells.
Feng PH; Lam B; Tseng SH; Kung YJ; Farmer E; Cheng MA; Hung CF
Cancer Immunol Immunother; 2020 Oct; 69(10):2147-2155. PubMed ID: 32468232
[TBL] [Abstract][Full Text] [Related]
35. Early changes in the immune microenvironment of oral potentially malignant disorders reveal an unexpected association of M2 macrophages with oral cancer free survival.
Bouaoud J; Foy JP; Tortereau A; Michon L; Lavergne V; Gadot N; Boyault S; Valantin J; De Souza G; Zrounba P; Bertolus C; Bendriss-Vermare N; Saintigny P
Oncoimmunology; 2021; 10(1):1944554. PubMed ID: 34239777
[TBL] [Abstract][Full Text] [Related]
36. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
[TBL] [Abstract][Full Text] [Related]
37. Combining epigenetic and immune therapy to overcome cancer resistance.
Gomez S; Tabernacki T; Kobyra J; Roberts P; Chiappinelli KB
Semin Cancer Biol; 2020 Oct; 65():99-113. PubMed ID: 31877341
[TBL] [Abstract][Full Text] [Related]
38. Decoding the influence of the immune system and immunotherapy targets on carcinomas: A hidden prism in oral cancer therapy.
Dhara V; Shetty SS; de Arruda JAA; Silva TA; Russo RC; Shetty NJ; Pidaparthi M; Wollenberg B; Rao VUS; Gopinath TPS
Dis Mon; 2023 Jan; 69(1):101353. PubMed ID: 35311656
[TBL] [Abstract][Full Text] [Related]
39. Emerging role of natural products in cancer immunotherapy.
Dong S; Guo X; Han F; He Z; Wang Y
Acta Pharm Sin B; 2022 Mar; 12(3):1163-1185. PubMed ID: 35530162
[TBL] [Abstract][Full Text] [Related]
40. Charge-switchable nanoparticles enhance Cancer immunotherapy based on mitochondrial dynamic regulation and immunogenic cell death induction.
Zhao M; Li J; Liu J; Xu M; Ji H; Wu S; Chen D; Hu H
J Control Release; 2021 Jul; 335():320-332. PubMed ID: 34062192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
